Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267488 · ClinicalTrials.gov registry record · Phase 2
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
A Phase 2 study of Endometrial Cancer and Neoplasms, Endometrial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT00267488 is a Phase 2 study of Endometrial Cancer and Neoplasms, Endometrial that has completed, run by GlaxoSmithKline. The registered enrollment target is 70 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00267488, a Phase 2 study of Endometrial Cancer and Neoplasms, Endometrial, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.
Conditions Studied
Interventions
- DRUG topotecan
Study Locations (20)
Florida
- GSK Investigational Site - Coral Gables
- GSK Investigational Site - Lakeland
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
California
- GSK Investigational Site - La Jolla
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Newport Beach
Illinois
- GSK Investigational Site - Chicago
- GSK Investigational Site - Hinsdale
South Carolina
- GSK Investigational Site - Columbia
- GSK Investigational Site - Greenville
Tennessee
- GSK Investigational Site - Chattanooga
- GSK Investigational Site - Knoxville
Colorado
- GSK Investigational Site - Engelwood
Georgia
- GSK Investigational Site - Atlanta
Louisiana
- GSK Investigational Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267488
The ClinicalTrials.gov registry entry for NCT00267488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (87% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which topotecan is the first listed.
NCT00267488 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00267488 about?
NCT00267488 is a clinical study titled "Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer". The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.
What is the current status of trial NCT00267488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2005-10. Estimated completion is 2007-12.
What conditions does trial NCT00267488 study?
This clinical trial studies the following conditions: Endometrial Cancer, Neoplasms, Endometrial.
What interventions are being tested in trial NCT00267488?
The interventions under investigation include: topotecan (DRUG).
Who is sponsoring clinical trial NCT00267488?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00267488 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.